Long-Term Functional Outcomes after Treatment for Localized Prostate CancerMatthew J. Resnick, David F. Penson, R. Lawrence Van Horn et al.|New England Journal of Medicine|2013Cited by 975
136 INFLUDENCE OF RACE AND COMORBIDITY ON THERAPY FOR PROSTATE CANCER: EVOLUTION OVER 15 YEARSAmee Morgans, David F. Penson, Daniel A. Barocas et al.|The Journal of Urology|2013Cited by 0
449 THE BURDEN OF PRE-TREATMENT URINARY, SEXUAL, AND BOWEL DYSFUNCTION ACROSS TWO DECADES OF PROSTATE CANCER: RESULTS FROM PCOS AND CEASARMatthew J. Resnick, David F. Penson, Daniel A. Barocas et al.|The Journal of Urology|2013Cited by 0
653 LONG TERM QUALITY OF LIFE OUTCOMES FOLLOWING TREATMENT FOR CLINICALLY LOCALIZED PROSTATE CANCER: RESULTS FROM THE PROSTATE CANCER OUTCOMES STUDYMatthew J. Resnick, David F. Penson, Kang-Hsien Fan et al.|The Journal of Urology|2012Cited by 0
Influence of age on incident diabetes (DM) and cardiovascular disease (CVD) among prostate cancer survivors receiving androgen deprivation therapy (ADT).Alicia K. Morgans, David F. Penson, Kang-Hsien Fan et al.|Journal of Clinical Oncology|2014Cited by 0